US20160256426A1 - Composition preventing necrotic enteritis in galloanserans - Google Patents

Composition preventing necrotic enteritis in galloanserans Download PDF

Info

Publication number
US20160256426A1
US20160256426A1 US15/029,230 US201415029230A US2016256426A1 US 20160256426 A1 US20160256426 A1 US 20160256426A1 US 201415029230 A US201415029230 A US 201415029230A US 2016256426 A1 US2016256426 A1 US 2016256426A1
Authority
US
United States
Prior art keywords
glycerol ester
ester composition
weight
composition according
glyceryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/029,230
Inventor
Filip Van Immerseel
Richard SYGALL
Karolien Van DRIESSCHE
Richard Ducatelle
Conrad Gerard SCHWARZER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perstorp AB
Original Assignee
Perstorp AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perstorp AB filed Critical Perstorp AB
Publication of US20160256426A1 publication Critical patent/US20160256426A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention refers to the use of a glycerol ester composition of at least one short chain fatty acid for preventing and/or alleviating necrotic enteritis in the gastric tract of galloanserans.
  • the glycerol ester composition comprises at least 75% by weight of glyceryl tributyrate, below 25% by weight of glyceryl dibutyrate and below 8% by weight of glyceryl monobutyrate.
  • the present invention also refers to the use of said composition for modulating the gut flora of galloanserans.
  • Necrotic enteritis is an acute infection affecting galloanserans.
  • Galloanserans are divided into the subgroups galliformes (landfowls) like chicken, turkey, grouse and pheasant, and anseriforms (waterfowls) like ducks, goose and swan.
  • Necrotic enteritis has become an emerging problem especially among poultry and is characterized by severe necroses of intestinal mucosa. The clinical illness is usually very short and often the only signs are a sudden increase in mortality. However, birds with depression, ruffled feathers, and diarrhea may also be seen. The gross lesions are primarily found in the small intestine (jejunum), which may be ballooned, friable, and contain a foul-smelling, brown fluid.
  • the causative agent is the gram-positive, obligate, anaerobic bacteria Clostridium perfringens. There are two primary C. perfringens types, A and C, associated with necrotic enteritis in galloanserans. Toxins produced by the bacteria cause damage to the small intestine, but also liver lesions, and mortality.
  • C perfringens is a nearly ubiquitous bacteria readily found in soil, dust, feces, feed, and used poultry litter. It is also a normal inhabitant of the intestines of healthy galloanserans.
  • necrotic enteritis depends on the presence of predisposing factors, such as mucosal damage caused by coccidial pathogens and feed containing high protein levels.
  • C. perfringens Because C. perfringens is nearly ubiquitous, it is important to prevent coccidiosis, as well as changes in the intestinal microflora that would promote its growth. This has earlier been accomplished by routinely adding antibiotics to the feed. However, since the ban of growth promoting antibiotics in the European Union in 2006, necrotic enteritis has become an emerging disease among, for instance, poultry. There is a great need for alternative methods to counteract this disease or malfunction.
  • the gut flora consists of a complex of microorganism species that live in the digestive tract.
  • gut is synonymous with intestinal and flora with microbiota and microflora.
  • the microorganisms perform a host of useful functions, such as fermenting unused energy substrates, training the immune system, preventing growth of harmful, pathogenic bacteria, regulating the development of the gut, producing vitamins for the host and producing hormones to direct the host to store fats.
  • some species are thought to be capable of causing diseases or malfunction by producing infection or increasing cancer risk for the host.
  • the present invention discloses the use of a glycerol ester composition for preventing and/or alleviating necrotic enteritis in the gastric tract of galloanserans, like chicken and turkey.
  • the use of said composition for modulating the gut flora of galloanserans is also disclosed.
  • Use of the composition according to the invention balances or normalizes the gut flora of galloanserans in such a way that the growth of pathogenic species is inhibited and diseases like necrotic enteritis are prevented.
  • One mechanism behind this effect is presently believed to be that the growth of helpful bacteria is favored and that this prevents the growth of pathogenic species by competing for nutrition and attachment sites to the epithelium of the colon.
  • butyric acid on gut health in poultry and other animals have been known for a long time.
  • Different distribution forms of butyric acid have also been explored, among them distributing butyric acid in the form of glycerol esters.
  • glyceryl monobutyrate as a feed-additive to promote animal gut health.
  • glycerol ester composition comprising mainly glyceryl tributyrate
  • the present invention refers to the use of a glycerol ester composition comprising a short chain fatty acid, which has proven to be an efficient way of preventing necrotic enteritis in galloanserans, such as broiler chicken.
  • the glycerol ester composition comprises at least 75% by weight of glyceryl tributyrate, below 25% by weight of glyceryl dibutyrate and below 8% by weight of glyceryl monobutyrate.
  • Butyric acid is known to have a positive effect on gut health in galloanserans.
  • the present invention shows that distributing the butyric acid mainly as glyceryl tributyrate is an efficient way of preventing necrotic enteritis in galloanserans, such as broiler chicken, and it has proven to be more efficient than distributing butyric acid mainly in the form of glyceryl monobutyrate.
  • the glycerol ester composition comprises at least 80% by weight of glyceryl tributyrate, below 20% by weight of glyceryl dibutyrate and below 5% by weight of glyceryl monobutyrate.
  • the glycerol ester composition comprises at least 85% by weight of glyceryl tributyrate, below 15% by weight of glyceryl dibutyrate and below 4% by weight of glyceryl monobutyrate.
  • the glycerol ester composition comprises at least 90% by weight of glyceryl tributyrate, below 10% by weight of glyceryl dibutyrate and below 2.5% by weight of glyceryl monobutyrate.
  • the amount of free butyric acid in the glycerol ester composition is below 1%, preferably below 0.5% and most preferably below 0.2% by weight. Keeping down the amount of free butyric acid also ensures that the pH in the glycerol ester composition is kept at a level where the glycerol ester will not undergo hydrolyzation into glycerol and free acid, hence, the product is kept stable.
  • the glycerol ester composition is adsorbed on an inert carrier, such as a silica carrier.
  • a silica carrier preferably comprises porous silica particles with an average particle size of 20-70 ⁇ m.
  • the glycerol ester composition is adsorbed on silica particles in a weight ratio of 50-80% glycerol ester and 20-50% silica particles.
  • the glycerol ester composition according to the present invention can be added to any commercially available feedstuffs for galloanserans.
  • the glycerol ester composition may be incorporated directly into commercially available feeds or fed supplementary to commercially available feeds.
  • the amount of glycerol ester composition fed to the galloanserans is from 0.05 to 1.5% by weight, preferably from 0.1 to 1.0% by weight of the galloanserans' daily feed ration.
  • the amount of said glycerol ester composition is administered over time intervals of 5-10 days and is decreased over a 1-5 week period.
  • the decrease of said amount is 20-50% of the amount given during the previous interval.
  • C. perfringens strain 56 The challenge strain used in the in vivo trials, C. perfringens strain 56, was isolated from the gut of a broiler chicken with necrotic lesions from a flock with weight gain problems and has been shown to be highly virulent in earlier in vivo trials.
  • the strain was classified as a type A strain (netB positive, beta-2 and enterotoxin negative) and produces moderate amounts of alpha toxin in vitro (Gholamiandehkordi et al., 2006).
  • the strain was grown for 24 h in Brain Heart Infusion broth (BHI, Oxoid, Basingstoke, England).
  • a ten-fold dose of the anticoccidial vaccine Paracox®-8 (Schering-Plough Animal Health, Brussels, Belgium), containing live, attenuated oocysts of Eimeria ( E. ) acervulina (two lines), E. brunetti, E. maxima, E. necatrix, E. praecox, E. mitis and E. tenella was used in this study.
  • Nobilis Gumboro D 78 vaccine (Schering-Plough Animal Health, Brussels, Belgium) was given in the drinking water.
  • the feed was provided by the Institute for Agricultural and Fisheries Research (ILVO). The tested products were mixed in the feed.
  • the Gumboro vaccine was given in the drinking water at day 16 in all groups. All groups were challenged orally one time a day with approximately 4.10 8 cfu C. perfringens strain 56 at days 17, 18, 19 and 20. At day 18 all birds were orally inoculated with a ten-fold dose of Paracox-8TM. At days 21, 22 and 23, 9 animals of each group were euthanized by intravenous sodium pentobarbital injection.
  • the GraphPad Prism Software, Inc was used to determine whether there were significant differences between groups. Statistical significance was determined at a P value of ⁇ 0.05.
  • Table 3 shows the number of birds with necrotic enteritis lesions for each group, at day 21, day 22 and day 23. Also, the total number of birds with lesions per group is shown.
  • glyceryl monobutyrate at the higher concentration is compared to the addition of glyceryl tributyrate, it is about the same weight of butyric acid that is added (making the assumption that glycerol and butyric acid have about the same molar weights).
  • glyceryl tributyrate gives a much better result (24% positive chicken in total for glyceryl tributyrate compared to 46% positive chicken in total for glyceryl monobutyrate at the higher concentration).
  • the embodiment example is to be construed as illustrative and not limiting in any way.
  • the glycerol ester composition may for example comprise a blend of glycerol esters of different short chain fatty acids, such as butyric acid, propionic acid and valeric acid. The dosage levels will then have to be calculated with respect to the total amount of glycerol esters.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention refers to the use of a glycerol ester composition of at least one short chain fatty acid for preventing and/or alleviating necrotic enteritis in the gastric tract of galloanserans. The glycerol ester composition comprises at least 75% by weight of glyceryl tributyrate, below 25% by weight of glyceryl dibutyrate and below 8% by weight of glyceryl monobutyrate. The present invention also refers to the use of said composition for modulating the gut flora of galloanserans.

Description

    FIELD OF THE INVENTION
  • The present invention refers to the use of a glycerol ester composition of at least one short chain fatty acid for preventing and/or alleviating necrotic enteritis in the gastric tract of galloanserans. The glycerol ester composition comprises at least 75% by weight of glyceryl tributyrate, below 25% by weight of glyceryl dibutyrate and below 8% by weight of glyceryl monobutyrate. The present invention also refers to the use of said composition for modulating the gut flora of galloanserans.
    • BACKGROUND OF THE INVENTION
  • Necrotic enteritis is an acute infection affecting galloanserans. Galloanserans are divided into the subgroups galliformes (landfowls) like chicken, turkey, grouse and pheasant, and anseriforms (waterfowls) like ducks, goose and swan. Necrotic enteritis has become an emerging problem especially among poultry and is characterized by severe necroses of intestinal mucosa. The clinical illness is usually very short and often the only signs are a sudden increase in mortality. However, birds with depression, ruffled feathers, and diarrhea may also be seen. The gross lesions are primarily found in the small intestine (jejunum), which may be ballooned, friable, and contain a foul-smelling, brown fluid.
  • The causative agent is the gram-positive, obligate, anaerobic bacteria Clostridium perfringens. There are two primary C. perfringens types, A and C, associated with necrotic enteritis in galloanserans. Toxins produced by the bacteria cause damage to the small intestine, but also liver lesions, and mortality.
  • C perfringens is a nearly ubiquitous bacteria readily found in soil, dust, feces, feed, and used poultry litter. It is also a normal inhabitant of the intestines of healthy galloanserans.
  • Development of necrotic enteritis depends on the presence of predisposing factors, such as mucosal damage caused by coccidial pathogens and feed containing high protein levels.
  • Because C. perfringens is nearly ubiquitous, it is important to prevent coccidiosis, as well as changes in the intestinal microflora that would promote its growth. This has earlier been accomplished by routinely adding antibiotics to the feed. However, since the ban of growth promoting antibiotics in the European Union in 2006, necrotic enteritis has become an emerging disease among, for instance, poultry. There is a great need for alternative methods to counteract this disease or malfunction.
  • An alternative to counteracting harmful bacteria like C. perfringens through antibiotics is to try to balance or normalize the gut flora. The gut flora consists of a complex of microorganism species that live in the digestive tract. In this context gut is synonymous with intestinal and flora with microbiota and microflora. The microorganisms perform a host of useful functions, such as fermenting unused energy substrates, training the immune system, preventing growth of harmful, pathogenic bacteria, regulating the development of the gut, producing vitamins for the host and producing hormones to direct the host to store fats. However, in certain conditions, some species are thought to be capable of causing diseases or malfunction by producing infection or increasing cancer risk for the host.
  • The present invention discloses the use of a glycerol ester composition for preventing and/or alleviating necrotic enteritis in the gastric tract of galloanserans, like chicken and turkey. The use of said composition for modulating the gut flora of galloanserans is also disclosed. Use of the composition according to the invention balances or normalizes the gut flora of galloanserans in such a way that the growth of pathogenic species is inhibited and diseases like necrotic enteritis are prevented. One mechanism behind this effect is presently believed to be that the growth of helpful bacteria is favored and that this prevents the growth of pathogenic species by competing for nutrition and attachment sites to the epithelium of the colon.
  • The positive effects of butyric acid on gut health in poultry and other animals have been known for a long time. Different distribution forms of butyric acid have also been explored, among them distributing butyric acid in the form of glycerol esters. In recent years, a lot of interest has been directed to the use of glyceryl monobutyrate as a feed-additive to promote animal gut health.
  • Use of a glycerol ester composition, comprising mainly glyceryl tributyrate, has now surprisingly been found to be a more efficient way of preventing necrotic enteritis in galloanserans, such as broiler chicken, compared to giving the animal butyric acid in the form of glyceryl monobutyrate.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention refers to the use of a glycerol ester composition comprising a short chain fatty acid, which has proven to be an efficient way of preventing necrotic enteritis in galloanserans, such as broiler chicken. The glycerol ester composition comprises at least 75% by weight of glyceryl tributyrate, below 25% by weight of glyceryl dibutyrate and below 8% by weight of glyceryl monobutyrate. Butyric acid is known to have a positive effect on gut health in galloanserans. The present invention shows that distributing the butyric acid mainly as glyceryl tributyrate is an efficient way of preventing necrotic enteritis in galloanserans, such as broiler chicken, and it has proven to be more efficient than distributing butyric acid mainly in the form of glyceryl monobutyrate.
  • According to one embodiment of the present invention the glycerol ester composition comprises at least 80% by weight of glyceryl tributyrate, below 20% by weight of glyceryl dibutyrate and below 5% by weight of glyceryl monobutyrate.
  • According to a preferred embodiment of the present invention the glycerol ester composition comprises at least 85% by weight of glyceryl tributyrate, below 15% by weight of glyceryl dibutyrate and below 4% by weight of glyceryl monobutyrate.
  • According to a more preferred embodiment of the present invention the glycerol ester composition comprises at least 90% by weight of glyceryl tributyrate, below 10% by weight of glyceryl dibutyrate and below 2.5% by weight of glyceryl monobutyrate.
  • Free butyric acid has a very unpleasant smell, which causes handling problems. These problems can be avoided by distributing the butyric acid in the form of glycerol esters. According to one embodiment of the present invention, the amount of free butyric acid in the glycerol ester composition is below 1%, preferably below 0.5% and most preferably below 0.2% by weight. Keeping down the amount of free butyric acid also ensures that the pH in the glycerol ester composition is kept at a level where the glycerol ester will not undergo hydrolyzation into glycerol and free acid, hence, the product is kept stable.
  • According to one embodiment of the present invention the glycerol ester composition is adsorbed on an inert carrier, such as a silica carrier. This allows the composition to be distributed as a dry product. Such a silica carrier preferably comprises porous silica particles with an average particle size of 20-70 μm. According to one embodiment of the present invention, the glycerol ester composition is adsorbed on silica particles in a weight ratio of 50-80% glycerol ester and 20-50% silica particles.
  • The glycerol ester composition according to the present invention can be added to any commercially available feedstuffs for galloanserans. The glycerol ester composition may be incorporated directly into commercially available feeds or fed supplementary to commercially available feeds.
  • According to one embodiment of the present invention the amount of glycerol ester composition fed to the galloanserans is from 0.05 to 1.5% by weight, preferably from 0.1 to 1.0% by weight of the galloanserans' daily feed ration.
  • According to another embodiment of the present invention the amount of said glycerol ester composition is administered over time intervals of 5-10 days and is decreased over a 1-5 week period.
  • According to yet another embodiment of the present invention the decrease of said amount is 20-50% of the amount given during the previous interval.
    • EMBODIMENT EXAMPLE
  • In vivo trial on the efficacy of glyceryl butyrates to control Clostridium perfringens-induced necrotic enteritis in broiler chicken.
    • Bacterial Strains and Vaccines
  • The challenge strain used in the in vivo trials, C. perfringens strain 56, was isolated from the gut of a broiler chicken with necrotic lesions from a flock with weight gain problems and has been shown to be highly virulent in earlier in vivo trials. The strain was classified as a type A strain (netB positive, beta-2 and enterotoxin negative) and produces moderate amounts of alpha toxin in vitro (Gholamiandehkordi et al., 2006).
  • For inoculation, the strain was grown for 24 h in Brain Heart Infusion broth (BHI, Oxoid, Basingstoke, England).
  • A ten-fold dose of the anticoccidial vaccine Paracox®-8 (Schering-Plough Animal Health, Brussels, Belgium), containing live, attenuated oocysts of Eimeria (E.) acervulina (two lines), E. brunetti, E. maxima, E. necatrix, E. praecox, E. mitis and E. tenella was used in this study. Nobilis Gumboro D 78 vaccine (Schering-Plough Animal Health, Brussels, Belgium) was given in the drinking water.
    • Animals and Housing
  • In this experiment, 114 broilers of mixed sex were used. They were obtained at 1 day old from a commercial hatchery. Before the trial, all rooms were decontaminated with Metatectyl® (Clim'oMedic) and with a commercial anticoccidial disinfectant (Bi-OO-cyst®; Biolink Ltd, York, UK). The birds were divided in 4 cages of 1.5 m2, on wood shavings. They were given drinking water and feed ad libitum. A 23 h/1 h light darkness program was applied.
    • Experimental Study Design
  • The first 7 days, the chickens were fed a starter diet and from day 8 until 15, a grower diet. Both the starter and the grower diet were a wheat/rye (43%/7.5%) based diet, with soybean meal as protein source. From day 17 onwards, the same diet was used with the exception that fishmeal (30%) was used as a protein source. The feed was provided by the Institute for Agricultural and Fisheries Research (ILVO). The tested products were mixed in the feed. The Gumboro vaccine was given in the drinking water at day 16 in all groups. All groups were challenged orally one time a day with approximately 4.108 cfu C. perfringens strain 56 at days 17, 18, 19 and 20. At day 18 all birds were orally inoculated with a ten-fold dose of Paracox-8™. At days 21, 22 and 23, 9 animals of each group were euthanized by intravenous sodium pentobarbital injection.
    • Model
  • TABLE 1
    Time schedule for the in vivo study.
    d 16 d 17 d 18 d 19 d 20 d 21 d 22 d 23
    Gumboro x
    Feed + x x x x x x x
    fishmeal
    Inoculation x x x x
    C. perfringens
    Paracox ® ×10 x
    Scoring x x x
    • Products Tested
      • Pen 1: positive control
      • Pen 2: glyceryl monobutyrate (adsorbed on a silica carrier), added to the feed at a lower concentration
      • Pen 3: glyceryl monobutyrate (adsorbed on a silica carrier), added to the feed at a higher concentration
      • Pen 4: glyceryl tributyrate (adsorbed on a silica carrier)
  • The products were added to the feed at the concentrations shown in Table 2 below:
  • TABLE 2
    Concentrations of products added to the feed (kg/ton)
    Glyceryl Glyceryl
    monobutyrate, monobutyrate, Glyceryl
    on silica carrier on silica carrier tributyrate,
    low conc high conc on silica carrier
    Week 1 5 7.5 5
    Week 2 2.5 6 2.5
    Week 3 2 5.5 2
  • Intestinal lesions in the small intestine (duodenum to ileum) were scored blinded as follows:
    • 0: no gross lesions
    • 1: congested intestinal mucosa
    • 2: small focal necrosis or ulceration (1-5 foci)
    • 3: focal necrosis or ulceration (5-16 foci)
    • 4: focal necrosis or ulceration (16 or more foci)
    • 5: patches of necrosis 2-3 cm long
    • 6: diffuse necrosis typical of field cases
  • Lesion scores of 2 or more were classified as necrotic enteritis positive
    • Statistical Analysis
  • The GraphPad Prism Software, Inc was used to determine whether there were significant differences between groups. Statistical significance was determined at a P value of <0.05.
    • Clinical Observations
  • No abnormal clinical observations were observed.
  • 3 chickens died during the trial.
  • −1 chicken died in pen 1
  • −2 chickens died in pen 3
  • Table 3 shows the number of birds with necrotic enteritis lesions for each group, at day 21, day 22 and day 23. Also, the total number of birds with lesions per group is shown.
  • TABLE 3
    Number of birds with macroscopic necrotic enteritis lesions on the
    three sampling days.
    glyceryl glyceryl
    monobutyrate, monobutyrate, glyceryl
    pos control low high tributyrate
    day 21 9/9 5/9 4/9 3/9 
    day 22 4/9 3/9 5/9 2/9 
    day 23  4/10  2/10 3/8 2/11
    total 17/28 10/28 12/26 7/29
    Total (%) 61 36 46 24
  • The percentage of positive chickens (with macroscopic lesion score =2) is shown in FIG. 1.
  • The results in FIG. 1 states that adding glyceryl tributyrate to the feed gives a significantly better result, with respect to preventing Clostridium perfringens-induced necrotic enteritis in broiler chicken, than adding glyceryl monobutyrate at either one of the two concentrations tested.
  • If the addition of glyceryl monobutyrate at the higher concentration is compared to the addition of glyceryl tributyrate, it is about the same weight of butyric acid that is added (making the assumption that glycerol and butyric acid have about the same molar weights). Despite this fact, glyceryl tributyrate gives a much better result (24% positive chicken in total for glyceryl tributyrate compared to 46% positive chicken in total for glyceryl monobutyrate at the higher concentration).
  • It is also remarkable that adding a lower concentration of glyceryl monobutyrate gives a better result than adding a higher concentration (36% positive chicken in total for glyceryl monobutyrate at the lower concentration compared to 46% positive chicken in total for glyceryl monobutyrate at the higher concentration).
  • The results show that using a glycerol ester composition according to the present invention is an effective way of preventing Clostridium perfringens-induced necrotic enteritis in galloanserans.
  • The embodiment example is to be construed as illustrative and not limiting in any way. The glycerol ester composition may for example comprise a blend of glycerol esters of different short chain fatty acids, such as butyric acid, propionic acid and valeric acid. The dosage levels will then have to be calculated with respect to the total amount of glycerol esters.
  • It may further prove to be useful to feed the glycerol ester composition to the animal for a shorter or longer period of time and to extrapolate the dosage levels accordingly.

Claims (20)

1. A glycerol ester composition comprising at least 75% by weight of glyceryl tributyrate, below 25% by weight of glyceryl dibutyrate and below 8% by weight of glyceryl monobutyrate, for use in prevention and/or alleviation of necrotic enteritis in the gastric tract of galloanserans.
2. A glycerol ester composition according to claim 1, wherein said necrotic enteritis is caused by Clostridium perfringens.
3. A glycerol ester composition according to claim 1, wherein said galloanserans are galliformes.
4. A glycerol ester composition according to claim 1, wherein said galloanserans are anseriforms.
5. A glycerol ester composition according to claim 1, wherein said glycerol ester composition comprises at least 80% by weight of glyceryl tributyrate, below 20% by weight of glyceryl dibutyrate and below 5% by weight of glyceryl monobutyrate.
6. A glycerol ester composition according to claim 1, wherein said glycerol ester composition comprises at least 85% by weight of glyceryl tributyrate, below 15% by weight of glyceryl dibutyrate and below 4% by weight of glyceryl monobutyrate.
7. A glycerol ester composition according to claim 1, wherein said glycerol ester composition comprises at least 90% by weight of glyceryl tributyrate, below 10% by weight of glyceryl dibutyrate and below 2.5% by weight of glyceryl monobutyrate.
8. A glycerol ester composition according to claim 1, wherein the amount of free butyric acid in said glycerol ester composition is below 1% by weight.
9. A glycerol ester composition according to claim 1, wherein the amount of free butyric acid in said glycerol ester composition is below 0.5% by weight.
10. A glycerol ester composition according to claim 1, wherein the amount of free butyric acid in said glycerol ester composition is below 0.2% by weight.
11. A glycerol ester composition according to claim 1, wherein said glycerol ester composition is adsorbed on a carrier, such as a silica carrier, thereby allowing said glycerol ester composition to be distributed as a dry product.
12. A glycerol ester composition according to claim 11, wherein said carrier comprises porous silica particles with an average particle size of 20-70 μm.
13. A glycerol ester composition according to claim 11, wherein said glycerol ester composition is adsorbed on silica particles in a weight ratio of 50-80% glycerol ester and 20-50% silica particles.
14. A glycerol ester composition according to claim 1, wherein said glycerol ester composition is fed to said galloanserans in an amount of between 0.05 to 1.5% by weight of the galloanserans' daily feed ration.
15. A glycerol ester composition according to claim 1, wherein said glycerol ester composition is fed to said galloanserans in an amount of between 0.1 to 1.0% by weight of the galloanserans' daily feed ration.
16. A glycerol ester composition according to claim 14, wherein said amount of said glycerol ester composition is administered over time intervals of 5-10 days and wherein said amount is decreased over a 1-5 week period.
17. A glycerol ester composition according to claim 16, wherein the decrease of said amount is 20-50% of the amount given during the previous interval.
18. A glycerol ester composition according to claim 15, wherein said amount of said glycerol ester composition is administered over time intervals of 5-10 days and wherein said amount is decreased over a 1-5 week period.
19. A glycerol ester composition according to claim 3, wherein said galloanserans are galliformes selected from the group consisting of chicken, turkey, grouse and pheasant.
20. A glycerol ester composition according to claim 4, wherein said galloanserans are anseriforms selected from the group consisting of ducks, goose and swan.
US15/029,230 2013-10-14 2014-10-06 Composition preventing necrotic enteritis in galloanserans Abandoned US20160256426A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1300646 2013-10-14
SE1300646-5 2013-10-14
PCT/SE2014/000123 WO2015057121A1 (en) 2013-10-14 2014-10-06 Composition preventing necrotic enteritis in galloanserans

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2014/000123 A-371-Of-International WO2015057121A1 (en) 2013-10-14 2014-10-06 Composition preventing necrotic enteritis in galloanserans

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/281,523 Division US9877945B2 (en) 2013-10-14 2016-09-30 Composition preventing necrotic enteritis in galloanserans

Publications (1)

Publication Number Publication Date
US20160256426A1 true US20160256426A1 (en) 2016-09-08

Family

ID=52828442

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/029,230 Abandoned US20160256426A1 (en) 2013-10-14 2014-10-06 Composition preventing necrotic enteritis in galloanserans
US15/281,523 Active US9877945B2 (en) 2013-10-14 2016-09-30 Composition preventing necrotic enteritis in galloanserans

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/281,523 Active US9877945B2 (en) 2013-10-14 2016-09-30 Composition preventing necrotic enteritis in galloanserans

Country Status (8)

Country Link
US (2) US20160256426A1 (en)
EP (1) EP3057441B1 (en)
CN (1) CN105636452A (en)
BR (1) BR112016006934B1 (en)
EA (1) EA031937B1 (en)
ES (1) ES2666909T3 (en)
PL (1) PL3057441T3 (en)
WO (1) WO2015057121A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111149919A (en) * 2020-01-14 2020-05-15 湖南泰丰动物药业有限公司 Glycerol butyrate compound for poultry as well as preparation method and application thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106107192B (en) * 2016-06-23 2019-11-01 杭州康德权饲料有限公司 One hatching egg feed additive for fowls and its application
WO2018052356A1 (en) * 2016-09-19 2018-03-22 Perstorp Ab A dietary supplement for balancing cholesterol.
CN107684554B (en) * 2017-08-29 2019-02-22 上海市儿科医学研究所 Application of the butyric acid compound in preparation prevention and treatment NEC drug
CN107736614A (en) * 2017-08-29 2018-02-27 上海市儿科医学研究所 Nutritional preparation containing butyric acid
EP3809869A1 (en) * 2018-06-22 2021-04-28 Basf Se Compositions for animals and uses thereof
WO2020226548A1 (en) * 2019-05-09 2020-11-12 Perstorp Ab Antioxidant composition for animal feed

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1600887A (en) * 1968-10-04 1970-08-03 Glyceryl triisobutyrate animal food - additive
US5569680A (en) * 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
US6217915B1 (en) * 1998-10-14 2001-04-17 Wisconsin Alumni Research Foundation Feed additive that increases availability of butyric acid and non-digestible oligosaccharides in the G.I. tract
FR2819686A1 (en) * 2001-01-23 2002-07-26 Xeris THE USE OF TRIBUTYRIN IN ANIMAL FEEDING AND CORRESPONDING FOOD ADDITIVE
ITFI20050024A1 (en) * 2005-02-14 2006-08-15 Fernando Cantini LIPIDS FOR ANIMAL FEEDING
DK2258219T4 (en) * 2005-04-27 2022-08-29 Nutricia Nv Nutrition with lipids and non-digestible saccharides
IT1393045B1 (en) * 2009-03-16 2012-04-11 Cantini COMPOSITIONS CONTAINING MONOGLICERIDES OF ORGANIC ACIDS FROM C1 TO C7 AND GLYCEROL, THEIR PREPARATION AND USE AS ANTIBACTERIALS IN THE ZOOTECHNY.
BRPI0902564A2 (en) * 2009-08-17 2011-05-03 Auster Nutricao Animal Ltda composed of 1 monopropionine and its isomer 3 monopropionine as preservatives of animal feed, grain and flour
US20110052675A1 (en) 2009-08-29 2011-03-03 Eric Yueh-Lang Sheu Orally Disintegrting Forms for Sustained Release and Controlled Release
CN101905025B (en) * 2010-07-20 2012-05-02 浙江大学 Preparation method for protective agent of intestinal mucosal barrier
ES2386474B1 (en) * 2011-01-21 2013-07-09 Norel, Sa ADDITIVES FOR ANIMAL FEEDING.
CN103561732A (en) * 2011-04-11 2014-02-05 阿克西里亚药品公司 Therapeutic compounds
CN102187945B (en) * 2011-07-01 2012-08-15 上海万萌生物科技有限公司 Additive for balancing gastrointestinal health of animals

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111149919A (en) * 2020-01-14 2020-05-15 湖南泰丰动物药业有限公司 Glycerol butyrate compound for poultry as well as preparation method and application thereof

Also Published As

Publication number Publication date
EP3057441A1 (en) 2016-08-24
EP3057441B1 (en) 2018-03-21
EA201690767A1 (en) 2016-07-29
CN105636452A (en) 2016-06-01
BR112016006934A8 (en) 2020-02-27
US9877945B2 (en) 2018-01-30
ES2666909T3 (en) 2018-05-08
PL3057441T3 (en) 2018-07-31
EA031937B1 (en) 2019-03-29
BR112016006934B1 (en) 2020-11-17
US20170087115A1 (en) 2017-03-30
WO2015057121A1 (en) 2015-04-23
EP3057441A4 (en) 2017-04-12
BR112016006934A2 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
US9877945B2 (en) Composition preventing necrotic enteritis in galloanserans
US8227235B2 (en) Compositions and methods for controlling diseases in animals
Williams Intercurrent coccidiosis and necrotic enteritis of chickens: rational, integrated disease management by maintenance of gut integrity
EP3057440B1 (en) Formulation preventing necrotic enteritis in galloanserans
Hofacre et al. Efficacy of butyric and valeric acid esters in a necrotic enteritis challenge model
US10420745B2 (en) Composition inhibiting gram-positive, pathogenic bacteria
Shojadoost et al. Effects of virginiamycin against experimentally induced necrotic enteritis in broiler chickens vaccinated or not with an attenuated coccidial vaccine
Spring The move away from antibiotic growth promoters in Europe.
JP7092785B2 (en) Feed additive preparation, its manufacturing method and usage method
US20230218681A1 (en) Brevundimonas sp for use in disease prevention and treatment
Botlhoko Performance of Clostridium perfringens-challenged broilers inoculated with Effective Microorganisms
AU2014201726A1 (en) Compositions and methods for controlling disease in animals
Nollet et al. Control of Clostridium perfringens Induced Necrotic Enteritis in Broilers by Target Released Butyric Acid, Fatty Acids and Essential Oils
BG1246U1 (en) Foods with paromomycine for poultry and other birds

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION